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talisations and 2.3 physician visits speciﬁcally for the treatment
of asthma exacerbations in the last 12 months. Patients in other
groups consumed more resources. Patients with mild persistent
asthma had 0.57 emergency room visits, 0.09 hospitalisations
and 3.1 physician visits. The means for moderate patients were
0.61, 0.25 and 3.66 respectively, and for severe patients 1.22,
1.98 and 6.22. Patients in Germany and France were most likely
to seek primary care treatment; though patients in Italy and the
UK were most likely to be hospitalised. CONCLUSION: The
data show that the likelihood of resource use of patients with
exacerbations of asthma increases with the underlying level of
severity. From these data, it is clear that better control and man-
agement of asthma exacerbations can result in resource use
savings.
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OBJECTIVES: To compare efﬁcacy and safety of salmeterol and
montelucast in adults with chronic bronchial asthma and cost-
effectiveness from payer’s and social perspective. METHODS:
The analysis was based on a systematic review. The efﬁcacy and
safety of salmeterol and montelucast were compared. Costs were
estimated on the basis of current cost of medication and pro-
ductivity loss in Poland. The time horizon of 12 weeks was
taken. The ratio of cost difference and efﬁcacy difference
(episode-free days—EFD) was calculated in incremental analy-
sis. RESULTS: The efﬁcacy analysis showed that statistically sig-
niﬁcant higher EFD ratio is achieved with salmeterol (32%) than
with montelucast (26%). Direct and indirect cost analyses of the
two options show that lower costs are generated by the use of
salmeterol. The use of montelucast in place of salmeterol results
in smaller health beneﬁt, and concomitantly, higher treatment
costs. The use of salmeterol in place of montelucast in a period
of 12 weeks in one patient is associated with gain of additional
5 days free of asthma symptoms. The estimated difference in a
period of 12 weeks of administration is approximately PLN 157
(34€) and PLN 248 (54€) per patient from payer’s and social per-
spective, respectively favouring salmeterol. The multivariate sen-
sitivity analysis was performed and conﬁrmed the robustness of
results. CONCLUSIONS: Salmeterol is a dominant option in
relation to montelucast in the treatment of bronchial asthma.
Salmeterol should be used before administration of montelucast.
Both perspectives concluded that administration of salmeterol
will result in payers budget savings—PLN680 (149€) per one
patient year. Conducting of prospective studies of indirect cost
of asthma treatment is recommended.
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OBJECTIVES: Assessment of efﬁcacy and safety of ﬂuticasone
and montelucast in treatment of adult patients with chronic
bronchial asthma and cost-effectiveness from payer’s and social
perspective. METHODS: Comparison of efﬁcacy and safety
were based on valid RCTs found in systematic reviews. Costs
were estimated on the basis of current cost of medications and
productivity loss in Poland. In the incremental analysis, the ratio
of social cost difference and efﬁcacy difference was calculated.
Multivariate sensitivity analysis was performed. RESULTS: Sta-
tistically signiﬁcantly higher efﬁcacy of ﬂuticasone over mon-
telucast has been demonstrated in relation to the following end
points: asthma symptom score, episode-free days, and supple-
mental rescue medications. There is no signiﬁcant difference
among treatment groups with respect to exacerbations and other
adverse events. Both options are safe and no difference in safety
has been demonstrated. The use of montelucast instead of ﬂuti-
casone results in smaller health beneﬁt for the patients, and con-
comitantly, higher treatment costs. The estimated difference in a
period of 24 weeks of administration is approximately PLN 733
(163€) and PLN 1401 (306€) per patient from payer’s and social
perspective, respectively favouring ﬂuticasone. The use of ﬂuti-
casone in place of montelucast for a period of 24 weeks in one
patient is associated with gained additional 14.6 days free of
asthma symptomps. Multivariate sensitivity analysis conﬁrmed
robustness of the results. CONCLUSIONS: Based on the con-
ducted cost-effectiveness analysis, it may be concluded that ﬂu-
ticasone is a dominant option over montelucast in the treatment
of bronchial asthma. Both perspectives concluded that adminis-
tration of ﬂuticasone will result in payers budget savings—
PLN1596 (348€) per one patient year. Prospective studies on
indirect costs of asthma treatment methods should be conducted.
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OBJECTIVES: Assess whether a disease management program
of asthma (DMPA) improves quality of care and reduces costs
compared to standard care (SC). METHODS: A prospective
“Before/After” quasi-experimental design was chosen. SC was
observed during the ﬁrst 18 months. DMPA involved training
doctors in existing guidelines in asthma, implementing asthma
education sessions and investments in computerised GP’s data
collection (with asthma template) Impact of DMPA was studied
in the subsequent 18 months. Control rate of asthma (CRA) was
deﬁned according to the Canadian asthma consensus criteria,
quality of life (QOL) measured by the Juniper scale and direct
and productivity costs assessed from the perspective of society.
The expenditure discount rate was three percent (3%). Three
regions were followed in parallel, to conﬁrm trends observed on
the experimental site were due to the DMPA. RESULTS: A total
of 32 volunteer general practitioners and 313 asthmatic patients
were recruited on the experimental site, of which 145 patients
took part in both phases of the study. There was an absolute
improvement on the average quarterly CRA of 11% (p < 0.003):
65% (±3%) in the DMPA group vs. 54% (±3%) for the SC
group; a relative gain of 20%. Differences in the patient’s QOL
were signiﬁcant in favour of DMPA (p < 0.05) for three domains
and on the overall score. Absolute reduction in the average quar-
terly costs reached 24% (p < 0.003): 247€ in the DMPA group
compared to 187.4€ for the SC group. Asthma drug costs were
not signiﬁcantly modiﬁed (p = 0.129). Meanwhile, in the paral-
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lel sample (n = 137) the average quarterly costs had increased by
13% (ns). CONCLUSIONS: Computerised data collection per-
formed by the doctor provide detailed information about diag-
nosis, treatments, and referrals making possible the study of
patient pathways and costs. DPMA is cost-effective in provision
of care.
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OBJECTIVES: Comparison of annual medication costs in a 
population-based study using a prediction formula based on 7
day medication history to cost data provided by health insurance
companies. METHODS: The KORA Asthma and Allergy 
study evaluated cost of illness due to asthma and allergies in a
population-based case-control design. Medication costs origi-
nated from a 7 day medication history (interview) and from
health insurance data. Drugs documented per interview were
assigned an average price per deﬁned daily dose (DDD) for each
standard package size group. Weekly medication costs were
extrapolated by multiplying price per DDD (medium package
size) by predicted length of intake according to general ATC
group. For consenting subjects, all medications reimbursed by
the health insurance companies for 1998 were obtained. The
annual total costs as well as cost differences between disease
groups were compared between both approaches. RESULTS: Of
1534 subjects participating in the KORA study, 1249 were
insured publicly and 63.8% of those consented to release their
health insurance data. Of 614 persons with prescribed medica-
tions according to insurance data, 233 (38%) reported no pre-
scribed medications during the interview. Median (inter-quartile
range) annual costs for this group were 37€ (16–103€). For the
other 381 subjects (62%), annual insurance costs were 260€
(116–638€) whereas predicted costs were higher (364€; 104–
863€). For subjects with asthma or allergy, predicted costs agreed
better with annual costs. Costs extrapolated from interview data
correlated signiﬁcantly (r = 0.63) with the annual costs. CON-
CLUSIONS: Estimation of annual medication costs for chronic
disease patients from seven day medication history data is feasi-
ble and estimates of group averages are similar to full annual
data from health insurance companies. For population-based
samples the latter approach is logistically more difﬁcult, is less
accepted by subjects, and does not encompass costs of most of
OTC drugs.
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OBJECTIVES: Estimating costs for different pharmaceutical
treatments based on data from clinical studies with discontinu-
ation is a problem with no general solution. Especially early dis-
continuations are often correlated with high initial costs, which
may have large impact on the estimates. A number of approaches
suggested in the literature for dealing with this problem were
investigated using data from clinical studies in the respiratory
ﬁeld to see if a consistent pattern could be found. METHODS:
Data from three large clinical studies (two concerning asthma,
one concerning COPD) were investigated for three different
approaches: PYA, Patient-Year Approach (linear extrapolation
for each patient to nominal duration of study), GMI, Group
Mean Imputation where missing data for a certain period is
replaced by the relevant group mean for corresponding period,
and GSA, Group-Sum Approach where data are summed over
treatment groups, implying that data are weighted according to
time in study for each patient. While the ﬁrst two approaches
are based on individual data and variation in estimates are easily
found by standard methods, precision in GSA estimates is found
by non-parametric bootstrapping. RESULTS: Data show that
discontinuations, and especially early discontinuations due to
exacerbations followed by intensive treatment, can have a sub-
stantial impact on the PYA approach, where the estimated mean
cost can be twice as high compared to the other approaches.
Demanding a certain time in study as qualifying for inclusion in
the analysis will gradually bring the results in agreement with
the GMI and GSA approach. CONCLUSIONS: In large clinical
studies, the GMI approach may be inconvenient because of
varying periods. The GSA approach in combination with non-
parametric bootstrapping for ﬁnding precision in estimates is a
simple and robust method.
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OBJECTIVES: To investigate if the results of four published
algorithms for calculating utility values from assessments of SF-
36 are in agreement with the responses of traditional efﬁcacy
variables assessed in clinical studies in the respiratory ﬁeld.
METHODS: Data from six different randomized clinical studies,
two from each of the disease areas of asthma, rhinitis and COPD,
comparing two treatments, are used in the investigation. Base-
line values before randomizing to study treatment are compared
for the algorithms as well as change during treatment. Change
during treatment is compared to the primary efﬁcacy variable in
each study. RESULTS: Mean utility values at baseline show a
consistent pattern across disease areas with large individual vari-
ation, with utility values ranging from 0.28 to 0.99 and with
mean values ranging from 0.58 to 0.82. Change during treat-
ment is small (0.00 to 0.11) and in most cases statistically non-
signiﬁcant when comparing treatments. Correlation with clinical
efﬁcacy is of moderate magnitude. CONCLUSION: The two
utility measures based on Standard Gamble or TTO seems to be
slightly better than those based on VAS or linear regression. The
pattern across the different disease areas is consistent for the dif-
ferent algorithms.
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